Page last updated: 2024-12-05

salsolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salsolidine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10302
CHEMBL ID320193
CHEBI ID94438
SCHEMBL ID177753
MeSH IDM0165921

Synonyms (76)

Synonym
CHEMBL320193
BB 0253136
BRD-A75140635-001-03-8
BRD-A75140635-003-03-4
6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro-isoquinoline
DIVK1C_006704
SDCCGMLS-0066785.P001
salsolidine
SPECTRUM4_001664
SPECTRUM_001738
SPECTRUM5_000567
MEGXP0_001951
OPREA1_776800
PRESTWICK3_000532
BSPBIO_000543
BSPBIO_003243
AB00052924
ACON1_002118
OPREA1_807785
NCGC00095670-02
NCGC00095670-01
KBIOSS_002218
KBIO2_007354
KBIO2_004786
KBIO3_002463
KBIO1_001648
KBIOGR_002187
KBIO2_002218
SPECTRUM2_001626
PRESTWICK0_000532
PRESTWICK1_000532
SPECPLUS_000608
SPECTRUM3_001612
SPBIO_002464
SPBIO_001691
SPECTRUM1504022
PRESTWICK2_000532
BPBIO1_000599
NCGC00095670-03
AKOS000268900
6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline
1,2,3,4-tetrahydro-6,7-dimethoxy-1-methylisoquinoline
A831633
5784-74-7
CCG-38746
NCGC00017169-03
NCGC00017169-02
NCGC00017169-04
(+-)-salsolidine
1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
n-norcarnegine
isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-
FT-0635850
1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-isoquinoline
AKOS016038394
SCHEMBL177753
HMS3561J09
(+)-salsolidine
6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline #
sr-01000842149
SR-01000842149-3
SR-01000842149-4
mfcd00694774
CHEBI:94438
CS-0042225
HY-22385
Q27166300
2-bromo-3-fluorophenyln,n-diethylcarbamate
E78563
SB37767
MS-23136
DTXSID20959384
38520-68-2
EN300-186699
1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-isoquinolin
isoquinoline,1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency13.33590.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID211657Neurotoxicity against human neuroblastoma SH-SY5Y cells using MTT dye conversion assay2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Neuroprotective or neurotoxic activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline and related compounds.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's3 (25.00)29.6817
2010's6 (50.00)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.61 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]